

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

AMNEAL PHARMACEUTICALS LLC AND  
AMNEAL PHARMACEUTICALS OF NEW YORK, LLC,  
Petitioners,

v.

ALMIRALL, LLC,  
Patent Owner.

---

Case IPR2018-00608  
Patent 9,161,926

---

**DECLARATION OF JULIE HARPER, M.D. IN SUPPORT OF PATENT  
OWNER'S RESPONSE TO PETITION FOR *INTER PARTES* REVIEW**

## TABLE OF CONTENTS

	Page
I. INTRODUCTION .....	1
A. Background and Qualifications .....	1
B. Materials Considered.....	4
II. SUMMARY OF OPINIONS.....	11
III. LEGAL STANDARDS .....	14
IV. THE '926 PATENT .....	16
V. PERSON OF ORDINARY SKILL IN THE ART .....	19
VI. EFFECTIVE FILING DATE OF THE '926 PATENT.....	20
VII. BACKGROUND RELATING TO THE INVENTION.....	20
A. Acne.....	22
1. <i>Causes of Acne</i> .....	23
2. <i>Prior Art Acne Treatments</i> .....	28
B. Rosacea.....	39
VIII. Petitioner's Prior Art References.....	43
A. WO 2009/061298 ("Garrett") (Ex. 1004).....	44
B. International Publ. No. WO 2010/072958 A2 ("Nadau-Fourcade") (Ex. 1005) .....	46
C. Giulia Bonacucina et al., <i>Characterization and stability of emulsion     gels based on acrylamide/sodium acryloyldimethyl taurate copolymer</i> , 10 Am. Assoc. of Pharmaceutical Scientists PharmSciTech 368 (2009) ("Bonacucina") (Ex. 1015).....	47
D. U.S. Patent Publ. No. 2006/0204526 ("Lathrop") (Ex. 1007) .....	47

E.	U.S. Patent Publ. No. 2010/0029781 (“Morris”) (Ex. 1008) .....	48
F.	David W. Osborne, <i>Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products</i> , 10 J. Cosmetic Dermatology 324 (2011) (“Osborne I”) (Ex. 1009) .....	48
G.	Aczone Gel 5% Package Insert (2005) (“2005 Aczone 5% PI”) (Ex. 1010) .....	50
H.	U.S. Patent No. 7,820,186 (“Orsoni”) (Ex. 1011).....	52
I.	Epiduo Gel Prescribing Information (2008) (“Epiduo PI”) (Ex. 1012) .....	53
J.	U.S. Patent Publ. No. WO 2007/0190019 (“Guo”) (Ex. 1013) .....	54
K.	U.S. Patent No. 5,863,560 (“Osborne II”) (Ex. 1016) .....	55
L.	Viscosity of Carbopol® Polymers in Aqueous Systems (“Lubrizon Technical Data Sheet”) (Ex. 1020).....	55
M.	Formulating Semisolid Products (“Lubrizon Pharmaceutical Bulletin 21”) (Ex. 1021).....	56
N.	V. E. Gottfried Wozel, <i>Innovative use of Dapsone</i> , 28 Dermatol Clin 599 (2010) (“Wozel”) (Ex. 1022).....	56
O.	Diane M. Thiboutot et al., <i>Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris</i> , 46 Clin Pharmacokinet 697 (2007) (“Thiboutot”) (Ex. 1023) .....	56
P.	Rebecca Nguyen and John Su, <i>Treatment of acne vulgaris</i> , 21 Pediatrics and Child Health 119 (2010) (“Nguyen”) (Ex. 1024).....	57
Q.	Hywel C. Williams et al., <i>Acne vulgaris</i> , 379 The Lancet 361 (2012) (“Williams”) (Ex. 1025) .....	57
R.	Seppic Sepineo™ P 600 Brochure (2008) (Ex. 1026) .....	58
S.	Laurie Barclay, <i>Use of Topical Corticosteroids for Dermatological conditions Reviewed</i> , www.medscape.com (January 21, 2009) (“Barclay”) (Ex. 1027) .....	58

T.	Jong-Yun Kim et al., <i>Rheological properties and microstructures of Carbopol gel network system</i> , 281 Colloid Polym Sci 614 (2003) (“Kim”) (Ex. 1029).....	58
U.	Neutralizing Carbopol® and Pemulen® Polymers in Aqueous and Hydroalcoholic Systems (2002) (“Noveon Technical Data Sheet”) (Ex. 1030) .....	58
V.	Suleyman Piskin and Erol Uzunali, <i>A review of the use of adapalene for the treatment of acne vulgaris</i> , 3 Therapeutics & CLincial Risk Management 621 (2007) (“Piskin”) (Ex. 1032) .....	59
IX.	The Claims of the ’926 Patent Would Not Have been Obvious .....	59
A.	A Person of Ordinary Skill in the Art at the Time of the ’926 Patent Would Not Have Selected Dapsone. ....	60
B.	A Person of Ordinary Skill Would Not Have Selected a Dapsone Concentration of About 7.5%.....	70
C.	If a Person of Ordinary Skill Had Sought to Use Dapsone as Part of an Improved Acne Product, that Person Would Have Done So in Combination with Adapalene. ....	75
D.	The Combinations Asserted by Amneal Would Not Have Rendered the Claims Obvious. ....	80
1.	<i>Garrett in view of Nadau-Fourcade</i> .....	80
2.	<i>Garrett in view of Bonacucina</i> .....	85
X.	Conclusion .....	90

I, Julie Harper, declare as follows:

## **I. INTRODUCTION**

1. My name is Julie Harper, M.D. I am a practicing dermatologist and head of the Dermatology & Skin Care Center of Birmingham, Alabama—a practice that provides thousands of patients with dermatological care every year. I am also a Clinical Associate Professor in the Department of Dermatology at the University of Alabama-Birmingham. I have been asked by Patent Owner Almirall, LLC (“Almirall”) to offer my opinions in the above-captioned *inter partes* review of United States Patent No. 9,161,926 (the “’926 patent”). I understand that Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals of New York, LLC (collectively, “Amneal”) have petitioned for *inter partes* review of the ’926 patent, and request that the United States Patent and Trademark Office (“PTO”) cancel as unpatentable claims 1–6 of the ’926 patent.

2. This declaration sets forth my analyses and opinions based on the materials I have considered, as well as the bases for my opinions.

### **A. Background and Qualifications**

3. I am a practicing dermatologist and the head of the Dermatology and Skin Care Center of Birmingham, a practice in Alabama that provides comprehensive dermatology services to patients. I am also a Clinical Associate

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.